Rajapaksha Weranga, Khetan Riya, Johnson Ian R D, Blencowe Anton, Garg Sanjay, Albrecht Hugo, Gillam Todd A
Centre for Pharmaceutical Innovation (CPI), Clinical and Health Sciences, University of South Australia, Adelaide, SA, Australia.
Applied Chemistry and Translational Biomaterials (ACTB) Group, Clinical and Health Sciences, University of South Australia, Adelaide, SA, Australia.
Front Drug Deliv. 2024 Feb 1;4:1339936. doi: 10.3389/fddev.2024.1339936. eCollection 2024.
Ovarian cancers are a complex and heterogenic group of malignancies that are difficult to detect, diagnose and treat. Fortunately, considerable knowledge of ovarian cancer specific biomarkers has been generated, that is pertinent to the development of novel theranostic platforms by combining therapies and diagnostics. Genomic and proteomic data has been invaluable in providing critical biomolecular targets for ovarian cancer theranostic approaches. Exploitation of the wealth of biomarker research that has been conducted offers viable targets as beacons for ovarian cancer detection, diagnosis, and therapeutic targeting. These markers can be used in theranostics, a treatment strategy that combines therapy and diagnostics and is common in nuclear medicine, where radionuclides are used for both diagnosis and treatment. The development of theranostics has taken substantial focus in recent years in the battle against ovarian cancer. Yet to date only one theranostic technology has emerged in clinical practice. However, given the wealth of ovarian cancer biomarkers the field is poised to see the emergence of revolutionary disease treatment and monitoring outcomes through their incorporation into the development of theranostic strategies. The future of ovarian cancer treatment is set to enable precise diagnosis, targeted treatment, and vigilant monitoring. This review aims to assess the status of ovarian cancer diagnostic tools and biomarkers in practice, clinical development, or pre-clinical development, highlighting newly emerging theranostic applications.
卵巢癌是一类复杂且异质性的恶性肿瘤，难以检测、诊断和治疗。幸运的是，已经产生了大量关于卵巢癌特异性生物标志物的知识，这与通过结合治疗和诊断来开发新型诊疗平台相关。基因组和蛋白质组数据对于为卵巢癌诊疗方法提供关键生物分子靶点具有重要价值。对已开展的大量生物标志物研究的利用提供了可行的靶点，作为卵巢癌检测、诊断和治疗靶向的指引。这些标志物可用于诊疗学，这是一种将治疗和诊断相结合的治疗策略，在核医学中很常见，其中放射性核素用于诊断和治疗。近年来，诊疗学的发展在对抗卵巢癌的斗争中受到了极大关注。然而，迄今为止，临床实践中仅出现了一种诊疗技术。不过，鉴于丰富的卵巢癌生物标志物，通过将它们纳入诊疗策略的开发中，该领域有望出现革命性的疾病治疗和监测成果。卵巢癌治疗的未来将实现精确诊断、靶向治疗和严密监测。本综述旨在评估卵巢癌诊断工具和生物标志物在实践、临床开发或临床前开发中的现状，突出新出现的诊疗应用。
